[SPONSORED CONTENT] In biomedical research it’s accelerate or perish. Drug discovery is a trial-and-error process driven by simulations – faster simulations, enabled by compute- and data-intensive technologies, mean more runs in less time, resulting in errors identified and solutions achieved. Established in 1946, the Oklahoma Medical Research Foundation is a nonprofit research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders and aging-related diseases. OMRF discoveries led to the first, U.S.-approved therapy targeting sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, an autoimmune disease. The foundation’s research is enabled in part by advanced technology – accelerated clusters and high-performance data storage that support workloads fueled by massive data sets.
Oklahoma Medical Research Foundation Picks WekaIO Data Platform for Drug Discovery
CAMPBELL, Calif., March 2, 2021 – WekaIO (Weka), maker of fastest-growing data platform for artificial intelligence/machine learning, life sciences research and high performance data analytics (HPDA), today announced that the Oklahoma Medical Research Foundation (OMRF) has implemented Weka’s Limitless Data Platform to simplify, speed up, and scale their mixed workloads. By using Weka, OMRF said it can run more and concurrent research jobs in […]